Rapid Review Quiz: Hospital-Acquired Pneumonia

September 15, 2022

A recent review found that the incidence of VAP was higher among patients with COVID-19 than among patients with other causes of ARDS. Researchers also determined that VAP in patients with COVID-19 was frequently associated with treatment failure and recurrences, as well as abscess and empyema.

Researchers found that the combined effects of the extensive use of immunosuppressive agents plus COVID-19–associated immune alteration and pulmonary infarction explained high VAP incidence. They further highlighted the increasing use of multiplex polymerase chain reaction during the COVID-19 pandemic, which shortened the delay of bacterial identification and had an uncertain impact on appropriateness of antibacterial therapy and prognosis.

Learn more about VAP.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.